This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): MEM 1003
Description: MEM 1003 is an L-Type calcium channel modulator. The compound modulates neuronal calcium channels to regulate calcium ion flow into neurons, preventing the deleterious consequences of excessive levels of calcium entry. One of benefits of this modulation is that neurons remain more responsive to incoming signals, counteracting the reduced activity that normally occurs during aging.
Deal Structure: In June 2001, Memory entered into an agreement with Bayer for an exclusive, worldwide, sub-licensable license under certain Bayer patents and know-how related to MEM 1003 for the treatment of human peripheral and CNS-related disorders. Memory is obligated to make payments of up to $20.0 million upon achievement of specified milestones.
Memory is obligated to pay royalties during the term of the agreement based on a specified percentage of worldwide net sales of products covered by the license agreement, which increases at increasing net sales levels and varies depending on whether the sales are made by them or by a sub-licensee. Royalty payment obligations will end on a country by country basis upon the expiration of the last patent rights in a given country or after ten years from the first commercial sale of a product covered by the license agreement in a given country, whichever is longer.
In November 2008, Roche and Memory Pharmaceuticals announced that the two companies...See full deal structure in Biomedtracker
Partners: Bayer AG
MEM 1003 News
Additional information available to subscribers only: